Predicting response to epigenetic therapy

Marianne B Treppendahl, Lasse S Kristensen, Kirsten Grønbæk

    72 Citationer (Scopus)

    Abstract

    Drugs targeting the epigenome are new promising cancer treatment modalities; however, not all patients receive the same benefit from these drugs. In contrast to conventional chemotherapy, responses may take several months after the initiation of treatment to occur. Accordingly, identification of good pretreatment predictors of response is of great value. Many clinical parameters and molecular targets have been tested in preclinical and clinical studies with varying results, leaving room for optimization. Here we provide an overview of markers that may predict the efficacy of FDA- and EMA-approved epigenetic drugs.

    OriginalsprogEngelsk
    TidsskriftThe Journal of clinical investigation
    Vol/bind124
    Udgave nummer1
    Sider (fra-til)47-55
    Antal sider9
    ISSN0021-9738
    DOI
    StatusUdgivet - jan. 2014

    Fingeraftryk

    Dyk ned i forskningsemnerne om 'Predicting response to epigenetic therapy'. Sammen danner de et unikt fingeraftryk.

    Citationsformater